Apolipoprotein B Versus Non–High-Density Lipoprotein Cholesterol

ascular disease is already the most common cause of death in the developed world and by 2020 will become the leading cause of death in the developing world as well. 1 No society can afford to offer everyone every therapy.Accordingly, improving the identification of individuals at increased risk of cardiovascular disease to receive preventive therapy must be one of our highest priorities.The study by Pischon and colleagues, 2 which appears in this issue of Circulation and which demonstrates that apolipoprotein B (apoB) is superior to non-high-density lipoprotein cholesterol (non-HDL-C) to identify the risk of vascular events, represents an important step forward in this process.